US 11,884,733 B2
Antibody variable domains targeting the NKG2D receptor
Gregory P. Chang, Medford, MA (US); Ann F. Cheung, Lincoln, MA (US); Asya Grinberg, Lexington, MA (US); William Haney, Wayland, MA (US); Bradley M. Lunde, Lebanon, NH (US); and Bianka Prinz, Lebanon, NH (US)
Assigned to Dragonfly Therapeutics, Inc., Waltham, MA (US)
Appl. No. 16/967,216
Filed by Dragonfly Therapeutics, Inc., Waltham, MA (US)
PCT Filed Feb. 8, 2019, PCT No. PCT/US2019/017330
§ 371(c)(1), (2) Date Aug. 4, 2020,
PCT Pub. No. WO2019/157366, PCT Pub. Date Aug. 15, 2019.
Claims priority of provisional application 62/716,259, filed on Aug. 8, 2018.
Claims priority of provisional application 62/628,161, filed on Feb. 8, 2018.
Prior Publication US 2021/0054082 A1, Feb. 25, 2021
Int. Cl. C07K 16/00 (2006.01); C12P 21/08 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01)
CPC C07K 16/2851 (2013.01) [C07K 16/2803 (2013.01); C07K 16/283 (2013.01); C07K 16/32 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 14 Claims
 
1. An antigen-binding site that binds NKG2D, comprising an antibody heavy chain variable domain comprising a complementarity-determining region 1 (CDR1) sequence represented by the amino acid sequence of SEQ ID NO:48, a complementarity-determining region 2 (CDR2) sequence represented by the amino acid sequence of SEQ ID NO:30, and a complementarity-determining region 3 (CDR3) sequence represented by the amino acid sequence of SEQ ID NO:78, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO: 80, or SEQ ID NO:82; and an antibody light chain variable domain comprising
a CDR1 sequence identical to the amino acid sequence of SEQ ID NO:32, a CDR2 sequence identical to the amino acid sequence of SEQ ID NO:33, and a CDR3 sequence identical to the amino acid sequence of SEQ ID NO:34.